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ABSTRACT
Background. In endometrial cancer (EMCA), indocya-
nine green (ICG) sentinel lymph node (SLN) mapping has
been reported, mainly in conjunction with robotic surgery.
Objective. We aimed to evaluate detection rates, sensi-
tivity, and false negative (FN) rate of laparoscopic ICG
SLN mapping in EMCA, and to evaluate differences in
surgical outcomes between patients subjected to SLN
biopsy only versus lymphadenectomy.
Methods. A retrospective analysis of EMCA patients
undergoing ICG SLN mapping ± pelvic (PLND) and/or
para-aortic lymphadenectomy (PALND) was performed.
Detection rates were calculated for the entire cohort. Sen-
sitivity and FN rates were calculated for patients
undergoing lymphadenectomy after SLN mapping, and
surgical outcome was compared among patients undergo-
ing SLN mapping only versus lymphadenectomy.
Results. Of 75 patients, 33 underwent SLN mapping and
42 underwent SLN mapping followed by PLND/PALND.
Overall and bilateral detection rates were 96 % (72/75) and
88 % (66/75), respectively, and the median number of
removed SLNs, pelvic non-SLNs (NSLN) and para-aortic
NSLNs was 3, 27, and 19, respectively. With a FN rate of
8.3 %, only one patient had bilateral FN SLNs and a
metastatic para-aortal NSLN. Estimated blood loss (EBL)
and operative (OR) time were significantly lower in
patients undergoing SLN mapping only. No differences in
complication rates between patients undergoing SLN
mapping only and patients undergoing lymphadenectomy
were recorded.
Conclusions. Laparoscopic ICG SLN mapping has
excellent overall and bilateral detection rates and a low FN
rate. Compared with lymphadenectomy, SLN biopsy is
associated with significantly lower EBL and shorter OR
time.
Since its definition in 1988, surgical staging in
endometrial cancer (EMCA) has been controversial.1
Given the low risk of lymph node metastases in early-stage
disease, it is believed that performing a pelvic (PLND) and
para-aortic lymphadenectomy (PALND) in every patient is
harmful rather than helpful. Various methods have been
investigated to identify which patient benefit the most from
surgical staging. The most widespread method to triage
patients to surgical staging is via intraoperative identifi-
cation of pathologic risk factors at frozen section 2–6;
however, frozen section is limited in that it provides only
the risk of lymph node metastases. Thus, in patients
intraoperatively identified as low risk, no information on
lymph node status has been gathered.
Recently, interest has shifted from an intraoperative
evaluation and an all-or-nothing approach to sentinel
lymph node (SLN) mapping.7,8 Although SLN mapping is
well-established in other tumors, in National Comprehen-
sive Cancer Network (NCCN) guidelines its application in
EMCA was only recognized to be appropriate in 2014.9 In
gynecological cancers, SLN mapping with 99Tc, blue dye,
and indocyanine green (ICG), in conjunction with a near-
infrared (NIR) fluorescence imaging system, has been
reported.10–12 ICG seems to stand out over the other tracers
with regard to detection rates.13,14 In gynecologic oncol-
ogy, ICG SLN mapping has been reported, mainly in
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conjunction with a robotic platform.12,13 In the laparo-
scopic setting, its use has been reported by only two other
groups in patients with endometrial and cervical cancer,
and by our group in cervical cancer.14–18
The aim of this study was to evaluate overall and
bilateral detection rates, sensitivity, and false negative (FN)
rates of the laparoscopic ICG SLN mapping in EMCA.
Furthermore, we sought to evaluate differences in surgical
outcome between patients subjected to SLN biopsy only
versus full lymphadenectomy.
MATERIALS AND METHODS
A retrospective analysis of all patients with EMCA or
complex atypical hyperplasia (CAH) undergoing ICG SLN
mapping at our Institution between December 2012 and
September 2015 was performed. Data on SLN mapping
were collected prospectively. The study was approved by
the Institutional Review Board, and all patients signed
informed consent.
Patients underwent SLN mapping followed by laparo-
scopic lymph node biopsy, total hysterectomy (TLH) and
bilateral salpingo-oophorectomy (BSO). Routine preoper-
ative work-up included a transvaginal sonogram, as well as
a chest x-ray for low-risk tumors and a computed tomog-
raphy (CT) scan for high-risk tumors. Focused imaging
was performed based on clinical suspicion, and SLN
mapping was performed with intraoperative cervical ICG
injection. Following a diagnostic laparoscopy, the cervix
was injected submucosally, 1 cm deep in the stroma at the
four cardinal points, with a total of 8 ml of ICG. One vial
of 25 mg ICG powder (Pulsion) was previously sus-
pended with 5 ml of sterile water. The fluorescent signal
was then identified under NIR mode, and the SLNs excised
and sent to permanent pathology. Frozen section analysis
on the SLN was performed only in cases of suspicion for
metastasis. Suspicious non-SLNs (NSLNs) were removed
and sent for frozen section. At final histopathological
analysis, a complete ultrastaging was performed in all cases
[three slides of hematoxylin and eosin (H&E) 200 um,
immunohistochemistry (IHC) if negative]. After having
completed the TLH, the uterus was sent to frozen section
and, based on identification of tumor risk factors and
clinical judgment, a laparoscopic PLND and/or PALND
was performed. In our institution, patients with type 2
EMCA, or with type 1 poorly differentiated and deeply
invasive tumors, undergo a PPALND. Patients with type 1
well-differentiated lesions confined to the inner half of the
myometrium undergo a SLN biopsy only. All other patients
undergo a PLND.
Clinicopathologic characteristics were evaluated using
the basic descriptive statistics. Overall and bilateral
detection rates, sensitivity, and FN rate of the SLN map-
ping were calculated using Fisher’s exact test. The false
positive rate was defined as zero. The overall detection rate
was calculated by dividing the number of procedures in
which at least one SLN was identified by the total number
of procedures performed, and the bilateral detection rate
was calculated by dividing the number of procedures in
which at least one SLN was identified on each side of the
pelvis by the total number of procedures performed. A true
positive SLN was defined as a positive SLN identified with
histopathological techniques, independent of regional
lymph node status, while an FN SLN mapping was defined
as a bilateral negative SLN in combination with a meta-
static NSLN. The FN rate of the SLN mapping was
calculated for patients who underwent at least a PLND
after the SLN biopsy. Surgical data, including estimated
blood loss (EBL), operative (OR) time, and intra- and
postoperative complication rates, were compared among
the group of patients undergoing SLN mapping only and
those undergoing a full lymphadenectomy after the SLN
biopsy, using the unpaired t test. To reduce the bias pos-
sibly linked to additional radical procedures, patients
undergoing radical hysterectomy (RLH), radical colpec-
tomy, or other non-EMCA concomitant-related surgeries
were excluded from this analysis. Statistical analyses were
performed using the R software (version 3.1.0). All p
values were two-sided, and p values\0.05 were considered
statistically significant.
RESULTS
Seventy-five patients were included in the study; their
clinicopathologic characteristics are summarized in
Table 1.
A TLH/BSO and SLN biopsy was performed on 33
patients. Of the remaining 42 patients, 13 underwent a
PLND and 29 underwent a PPALND. Of the patients
undergoing a full retroperitoneal staging, two also under-
went an omentectomy. Three patients underwent an RLH
due to suspicion of parametrial invasion on preoperative
MRI in two cases, and vaginal involvement requiring a
colpectomy in one case; one of these patients underwent a
hemicolectomy for a concomitant colon cancer. All
patients undergoing an RLH underwent a PPALND after
the SLN biopsy. Conversion to laparotomy occurred in one
case, secondary to macroscopic metastatic lymph node
involvement. The median OR time was 220 min, and the
median EBL was 200 ml. Three intraoperative complica-
tions occurred, including one severe skin emphysema with
hypercapnia requiring an intensive care unit (ICU) admis-
sion, one bladder lesion occurring in a stage IIIB patient
undergoing a laparoscopic RLH and radical colpectomy,
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and one obturator nerve lesion. No ICG injection-related
complications were registered. Two major postoperative
complications occurred: one small bowel perforation
requiring a relaparotomy in a patient undergoing a full
laparoscopic surgical staging, and a large bowel anasto-
mosis breakdown requiring a relaparotomy in the patient
undergoing a hemicolectomy.
The median number of SLNs removed was three (range
0–11), and overall and bilateral SLN detection rates were
96 % (72/75) and 88 % (66/75), respectively. Data on SLN
mapping are summarized in Table 2. In two of the three
patients in whom the SLN mapping failed, the pelvis had
been previously irradiated, secondary to bladder cancer and
pelvic lymphoma, respectively. By excluding these patients
from the analysis, these rates rise to 98.6 % (72/73) and
90.4 % (66/73), respectively. Every patient in whom at
least one SLN could be identified mapped in the pelvis. In
5 % (4/75) of cases, additional SLNs were identified in the
para-aortic region; no isolated para-aortic SLN was
detected. The distribution of the SLNs is demonstrated in
Fig. 1. Of the patients considered to be at low risk at frozen
section, SLNs were metastatic in two cases.
Overall, 14.7 % (11/75) of patients had lymph node
metastases and, in all these cases, an SLN was detected
bilaterally. Pathological evaluation of the SLNs showed
micrometastases in four patients, all of which were diag-
nosed at H&E. Of the 42 patients in whom a PLND/
PPALND was performed, one FN mapping occurred: both
the bilateral SLNs in the pelvis and all the pelvic lymph
nodes were negative, whereas two para-aortic NSLNs had
metastatic disease. In another patient, four of five SLNs
were true positive in the right hemipelvis, whereas one
SLN in the left pelvis was FN as one NSLN had metastatic
disease. The calculated sensitivity of the SLN mapping was
91.7 %; the FN rate was 8.3 %.
Thirty-three patients underwent a TLH/BSO and SLN
biopsy, whereas 39 patients underwent the same surgical
procedures followed by a PLND/PPALND. EBL and OR
time were significantly lower among patients undergoing
TABLE 1 Clinicopathologic characteristics of patients
Patients (N = 75)
Median age, years (range) 65 (38–89)


























\50 % 46 (61.3)
[50 % 27 (36.0)
Patients with lymph node metastases 11 (14.7)
Surgical lymph node assessment
SLN biopsy only 33 (44.0)
SLN biopsy ? PLND 13 (17.3)
SLN biopsy ? PLND ? PALND 29 (38.7)
Median number of PLNs (range) 27 (10–48)
Median number of PALNDs (range) 19 (9–56)
Operations performed
Hysterectomy ? BSO 33 (44.0)
Hysterectomy ? BSO ? PLND 13 (17.4)
Hysterectomy ? BSO ? PLND ? PALND 26 (34.7)
Radical hysterectomy ? radical
colpectomy ? BSO ? PLND ? PALND
1 (1.3)
Radical hysterectomy ? hemicolectomy
? BSO ? PLND ? PALND
1 (1.3)





Data are expressed as n (%) unless otherwise specified
BMI body mass index, FIGO International Federation of Gynecology
and Obstetrics, SLN sentinel lymph node, PLND pelvic lymph node
dissection, PALND para-aortic lymph node dissection, BSO bilateral
salpingo-oophorectomy, PLNs pelvic lymph nodes
TABLE 2 Lymph node data
Overall SLN detection 72/75 (96.0)
Bilateral SLN detection 66/75 (88.0)
Unilateral SLN detection 6/75 (8.0)
No SLN detection 3/75 (4.0)
Median number of SLNs/patient (range) 3 (0–11)
Patients with lymph node metastasis 11/75 (14.7)
Macrometastasis 7/11 (63.6)
Micrometastasis 4/11 (36.4)
Isolated tumor cells 0
Data in parentheses represent percentages unless otherwise stated
SLN sentinel lymph node
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an SLN mapping only compared with patients undergoing
a full lymphadenectomy (200 ml vs. 300 ml, p\ 0.0001;
150 min vs. 300 min, p\ 0.0001), but no differences were
observed among intra- and postoperative complications in
the two groups.
DISCUSSION
Although two randomized trials failed to show any
benefit in EMCA patients who underwent a retroperitoneal
staging, lymph node assessment still represents the
cornerstone of EMCA staging.19,20 Lymph node status still
represents one of the most important prognostic factors
based on which adjuvant treatment is tailored.21–24
Our overall and bilateral detection rates of 96 % (72/75)
and 88 % (66/75), respectively, are among the highest
reported in the literature. Furthermore, by excluding two
patients who had been previously subjected to pelvic
radiation, these rates rise to 98.6 % (72/73) and 90.4 %
(66/73), respectively. We speculate that the radiation-in-
duced fibrosis alters the lymphatic flow, thus interfering
with the SLN mapping; therefore, pelvic radiation should
be a contraindication to SLN mapping. Similarly, Plante
et al. reported overall and bilateral detection rates of 96 and
88 %, with a negative predictive value of 98.7 % per side
in 50 patients with uterine malignancies undergoing a
laparoscopic SLN mapping.15 More recently, Buda et al.
compared the outcome of two different SLN mapping
tracers in 81 women with uterine malignancies undergoing
laparotomy or laparoscopic surgery.17 They reported higher
overall and bilateral detection rates in patients undergoing
SLN mapping with ICG compared with methylene blue.
Their overall and bilateral detection rates and negative
predictive value were 100, 88 and 100 %, respectively,
when ICG was used. This is in accordance with our pre-
viously published data in cervical cancer.14
We believe that the good results recorded in our series
are largely attributed to the tracer used. Desai et al.
reported an overall and bilateral detection rate of 86 and
52 %, respectively, using blue dye,10 while in the SENTI-
ENDO study, overall and bilateral detection rates were 89
and 69 %, respectively, using a combination of 99Tc and
blue dye.11 Solima et al. reported an overall detection rate
of 95 % after hysteroscopic injection of 99Tc; no data on
their bilateral detection rate are reported.25 With the uterus
being a midline structure, it is crucial to have a high
bilateral detection rate to avoid unilateral lymph node
dissections. Barlin et al. of the Memorial Sloan Kettering
Cancer Center (MSKCC), proposed an SLN mapping
algorithm for EMCA in which, in addition to the SLNs,
every suspected lymph node is biopsied and a monolateral
PLND is performed in those patients who map in only one
hemipelvis.26 A high bilateral detection rate leads to a
reduced number of bilateral and unilateral lymphadenec-
tomies, possibly reducing surgical morbidity. By applying
the MSKCC SLN mapping algorithm to our cohort of
patients, one and six patients would have undergone a
bilateral and monolateral PLND, respectively.
When SLN mapping is performed with ICG and the
robotic platform, overall and bilateral detection rates vary
between 87 and 82 and 97 and 57 % in the different series,
respectively.27–31 Our results correlate well with these data,
suggesting that the dye, rather than the robot, is account-
able for it.
In our study, one patient with a stage IIIB EMCA
underwent SLN mapping followed by full surgical staging.
Although SLN mapping also proved to be reliable in this
case, with the bilateral identification of true negative SLNs
we do not recommend relying on the SLN biopsy only in
patients with stages other than stage I.
Compared to other mapping protocols, we injected a
higher concentration of ICG. According to a recent meta-
analysis, a lower concentration of ICG may provide better
performance of the SLN mapping.32 In our hands, our
protocol worked well and in no case was the operative field
excessively stained.
In our study, every patient in whom at least one SLN
could be identified mapped in the pelvis. In 5 % (4/75) of
cases, additional SLNs were identified in the para-aortic
region. No isolated para-aortic SLNs were detected.
Although the cervical injection of the tracer is the most
common injection site in EMCA SLN mapping, there are
FIG. 1 Anatomic distribution of sentinel lymph node. Obturator
fossa 55 %, external iliac artery 32 %, common iliac artery 8 %,
aortic bifurcation 4 %, para-aortic area 1 %
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concerns that tumors located in the fundus may spread
through other lymphatic routes directly to the para-aortic
region. For this reason, some centers propose a hystero-
scopic tracer injection.31,33 In our series, only one case
presented an isolated para-aortic lymph node metastasis,
representing 2.4 % of the staged patients. This percentage
is in accordance with the risk of isolated para-aortic
metastasis reported by Mariani et al. in fully staged, high-
risk EMCA patients, providing further evidence that cer-
vical injection of the tracer represents a safe way to
perform SLN mapping in EMCA.34
Finally, we demonstrated that SLN biopsy is associated
with a shorter OR time and a lower EBL compared with full
surgical staging. Although these results may seem trivial,
they have not yet been reported in the literature. However,
our unique cohort of patients, including those who have
undergone a SLN biopsy only and patients who have
undergone SLN biopsy followed by a full lymphadenec-
tomy, allowed for such an analysis. Intra- and postoperative
complication rates are low and do not differ between the
two groups. These results confirm data from the literature
showing that, in experienced hands, a full laparoscopic
staging is a feasible procedure, with low complication
rates.35 The acquisition of the skills to perform a full pelvic
and para-aortic laparoscopic lymphadenectomy is long and
steep.36 Although SLN mapping seems to be more intuitive
and require less surgical skill, it is crucial that it is per-
formed accurately in order to avoid running the risk of
sampling the wrong lymph node. Furthermore, although it is
debated whether or not a full lymphadenectomy should be
performed in patients with metastatic SLNs, considering
that the MSKCC SLN mapping algorithm should be
applied, we believe that every physician who performs a
laparoscopic SLN mapping should have the skills to per-
form a full retroperitoneal staging.
Limitations of the study include its retrospective nature
and the relatively small sample size. On the other hand, the
prospective SLN mapping data collection, the relatively
large percentage of patients undergoing PLND/PALND,
and the thoroughness of the lymphadenectomy, as testified
by the large number of lymph nodes removed, signify the
strengths of the study.
CONCLUSIONS
This is the largest existing series on laparoscopic ICG
SLN mapping in EMCA. Laparoscopic ICG SLN mapping
in EMCA is characterized by high overall and bilateral
detection rates and low FN rates that compare favorably
with those reported when a robotic platform is used, sug-
gesting that the tracer, rather than the surgical approach, is
responsible for the SLN mapping outcome.
Compared with full surgical staging, SLN biopsy is
associated with significantly lower EBL and shorter OR
time, but no difference in intra- and postoperative com-
plications. In a dualistic model in which a
lymphadenectomy is fully performed or omitted based on
intraoperatively evaluated pathologic tumor characteristics,
ICG SLN mapping appears to represent a solomonic
solution that gathers important pathologic information at
low surgical expense.
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